厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床效果  

clinical effect of erlotinib combined whole brain radiotherapy (WBRT) in patients with brain metastases of non-small cell lung cancer (NSCLC)

作　　者：院刚[1] 郝灵芳[1] 

机构地区：[1]呼和浩特市第一医院放疗科,内蒙古呼和浩特010030

出　　处：《疾病监测与控制》2017年第11期890-891,共2页Journal of Diseases Monitor and Control

摘　　要：目的观察厄洛替尼联合全脑放疗(WBRT)治疗非小细胞肺癌脑转移临床意义。方法随机将收治的46例非小细胞肺癌脑转移患者分为两组。对照组给予WBRT治疗,观察组在对照组的基础上给予厄洛替尼治疗。比较两组疗效。结果观察组总有效率、中位生存时间及1年生存率等均显著优于对照组,差异有统计学意义(P﹤0.05)。结论厄洛替尼联合WBRT治疗非小细胞肺癌脑转移疗效理想,可明显提高病人的生存时间。Objective To investigate the effect of erlotinib combined WBRT in patients with brain metastases of NSCLC. Methods 46 cases with brain metastases of NSCLC from January 2014 to January 2015 were divided into two groups. The control group used WBRT, and observation group used erlotinib on the basis of control group. comparing efficacy of two groups. Results the total effective rate, median survival time and 1 year survival rate of observation group were significantly better than control group, the difference was statistically significant（P﹤0.05）. Conclusion the effect of erlotinib combined WBRT in the treatment of patients with brain metastases of NSCLC is ideal, and can improve the patient＇s survival time.

关 键 词：非小细胞肺癌脑转移 厄洛替尼 全脑放疗 

分 类 号：R734.2[医药卫生—肿瘤]